Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
957 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04628026 | Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 | recruiting | Phase 3 | 650 | University of UlmOTHER | 8 | Sep 9, 2026 | clinicaltrials |
| NCT05326308 | Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma(ARIADNE) | recruiting | — | 845 | iOMEDICO AGINDUSTRY | 2 | Sep 9, 2026 |
| clinicaltrials |
| NCT05386108 | Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer(ELECTRA) | recruiting | Phase 1 / Phase 2 | 73 | Stemline Therapeutics, Inc.INDUSTRY | 10 | Sep 9, 2026 | clinicaltrials |
| NCT05804318 | Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer(ARTIA-Prostate) | recruiting | N/A | 132 | Varian, a Siemens Healthineers CompanyINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT06175845 | Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma(ACTICCA-2) | recruiting | N/A | 130 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06315010 | Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis(REPOSE) | recruiting | Phase 2 | 20 | MedSIROTHER | 3 | Sep 9, 2026 | clinicaltrials |
| NCT07067437 | Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)(sfVAPBI) | recruiting | N/A | 250 | National Institute of Oncology, HungaryOTHER | 9 | Sep 9, 2026 | clinicaltrials |
| NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer(RAINFOL-03) | recruiting | Phase 3 | 660 | GenmabINDUSTRY | 19 | Sep 9, 2026 | clinicaltrials |
| NCT07328347 | Improving Dental Care for Patients With Head and Neck Tumors(OncoDent) | recruiting | N/A | 134 | University Medical Center GoettingenOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07549412 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) | recruiting | Phase 3 | 1,020 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 16 | Sep 9, 2026 | clinicaltrials |
| NCT07672236 | A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.(BEAM-Pain) | recruiting | Phase 3 | 150 | OncoZenge ABINDUSTRY | 4 | Sep 9, 2026 | clinicaltrials |
| NCT05091424 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 1 | 332 | Hoffmann-La RocheINDUSTRY | 10 | Sep 8, 2026 | clinicaltrials |
| NCT05307705 | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors(PIKASSO-01) | recruiting | Phase 1 | 260 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 8, 2026 | clinicaltrials |
| NCT05839379 | Targeted Pediatric High-Grade Glioma Therapy | recruiting | — | 350 | Nationwide Children's HospitalOTHER | 7 | Sep 8, 2026 | clinicaltrials |
| NCT06119581 | A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer(SUNRAY-01) | recruiting | Phase 3 | 1,264 | Eli Lilly and CompanyINDUSTRY | 29 | Sep 8, 2026 | clinicaltrials |
| NCT06561685 | A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 340 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT06564038 | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies(Soundtrack-E) | recruiting | Phase 1 / Phase 2 | 408 | AstraZenecaINDUSTRY | 13 | Sep 8, 2026 | clinicaltrials |
| NCT07100106 | A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer(MoonROSE) | recruiting | Phase 1 / Phase 2 | 285 | Genentech, Inc.INDUSTRY | 10 | Sep 8, 2026 | clinicaltrials |
| NCT07228832 | Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer(HARMONi-GI3) | recruiting | Phase 3 | 600 | Summit TherapeuticsINDUSTRY | 14 | Sep 8, 2026 | clinicaltrials |
| NCT07405801 | A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer | recruiting | Phase 2 | 80 | Hoffmann-La RocheINDUSTRY | 12 | Sep 8, 2026 | clinicaltrials |
| NCT07647328 | A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer(SERAFA-1) | recruiting | Phase 3 | 150 | AstraZenecaINDUSTRY | 9 | Sep 8, 2026 | clinicaltrials |
| NCT07806266 | EORTC Metastatic Breast Cancer Module Development | recruiting | — | 568 | University of LeedsOTHER | 14 | Sep 8, 2026 | clinicaltrials |
| NCT01949129 | Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia | recruiting | Phase 2 / Phase 3 | 1,800 | St. Anna KinderkrebsforschungOTHER | 31 | Sep 4, 2026 | clinicaltrials |
| NCT06274515 | A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies(REMERGE) | recruiting | Phase 4 | 320 | Hoffmann-La RocheINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT06787105 | Fruquintinib in Patients With Metastatic Colorectal Cancer(FRUQUENT) | recruiting | — | 150 | iOMEDICO AGINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07144319 | Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy(ENAiBLE) | recruiting | — | 500 | PhotocureINDUSTRY | 5 | Sep 4, 2026 | clinicaltrials |
| NCT07291037 | Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations(TROPION-Lung17) | recruiting | Phase 3 | 400 | AstraZenecaINDUSTRY | 21 | Sep 4, 2026 | clinicaltrials |
| NCT07803848 | Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status(SPACE-T) | recruiting | Phase 2 | 57 | AIO-Studien-gGmbHOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05533775 | A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma(iMATRIX GLO) | recruiting | Phase 1 / Phase 2 | 65 | Hoffmann-La RocheINDUSTRY | 13 | Sep 3, 2026 | clinicaltrials |
| NCT05583617 | A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma(PLYCOM) | recruiting | Phase 1 / Phase 2 | 200 | Hoffmann-La RocheINDUSTRY | 6 | Sep 3, 2026 | clinicaltrials |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)(OMAHA-003) | recruiting | Phase 3 | 1,310 | Merck Sharp & Dohme LLCINDUSTRY | 36 | Sep 3, 2026 | clinicaltrials |
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation(CodeBreaK 301) | recruiting | Phase 3 | 450 | AmgenINDUSTRY | 35 | Sep 3, 2026 | clinicaltrials |
| NCT06422143 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | recruiting | Phase 3 | 851 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 3, 2026 | clinicaltrials |
| NCT06445972 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | recruiting | Phase 1 / Phase 2 | 210 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 3, 2026 | clinicaltrials |
| NCT06921785 | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma(ARTEMIDE-HCC01) | recruiting | Phase 3 | 1,220 | AstraZenecaINDUSTRY | 20 | Sep 3, 2026 | clinicaltrials |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer(ReDiscover-2) | recruiting | Phase 3 | 540 | Relay Therapeutics, Inc.INDUSTRY | 24 | Sep 3, 2026 | clinicaltrials |
| NCT06989112 | DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer(DE-01) | recruiting | Phase 3 | 600 | AstraZenecaINDUSTRY | 23 | Sep 3, 2026 | clinicaltrials |
| NCT07005154 | A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | recruiting | Phase 2 | 218 | Astellas Pharma Global Development, Inc.INDUSTRY | 12 | Sep 3, 2026 | clinicaltrials |
| NCT07287150 | A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer(InavoPC) | recruiting | Phase 2 | 100 | Hoffmann-La RocheINDUSTRY | 12 | Sep 3, 2026 | clinicaltrials |
| NCT07413939 | RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive(BREnnA) | recruiting | Phase 2 / Phase 3 | 650 | Hoffmann-La RocheINDUSTRY | 25 | Sep 3, 2026 | clinicaltrials |
| NCT07549516 | A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany(ASC2ADHERE) | recruiting | — | 380 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07803315 | Hyperspectral Imaging in Robot-Assisted Partial Nephrectomy(HSI-Renal) | recruiting | — | 60 | University of LeipzigOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 2, 2026 | clinicaltrials |
| NCT06043817 | First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations | recruiting | Phase 1 / Phase 2 | 345 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT06284590 | Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients(INTACT/MeRCI) | recruiting | Phase 2 | 162 | Philogen S.p.A.INDUSTRY | 3 | Sep 2, 2026 | clinicaltrials |
Data updated 21 days agoSource updated unknownsource: clinicaltrials